The Company

lti-Agentic AI Platform Powered by Proprietary Systems Biology Engine Delivers Personalized Therapy Optimization and Investment Risk Assessment PLEASANTON, CA, UNITED STATES, September 10, 2025 /EINPresswire.com/ -- GNQ Insilico Inc. (“GNQ”...

GNQ Insilico, Inc. (“GNQ” or “the Company”), a cutting-edge TechBio platform company, announced results from its proprietary Drug Assessment Platform. GNQ’s platform represents a breakthrough in computational drug development and...

GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, demonstrated the advanced capabilities of its AI-powered Drug Assessment Platform in addressing critical treatment optimization challenges for patients with...

Sudhir Saxena, Chief Technology Officer of GNQ Insilico, Inc. (GNQ), was invited by Deloitte Consulting to present GNQ’s multi-omics approach to personalized medicine through AI-powered digital twins at the Quantum...

GNQ Insilico’s AI-Driven Digital Twins Platform Shows Promising Results in Simulating Effects of a Drug on Synthesized Digital Twins June 18, 2024 GNQ Insilico, Inc. (“GNQ” or “the Company”), a...

GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, announced the successful development and validation of its AI-powered Drug Assessment Platform prototype for clomiphene citrate dose optimization. The...

SAN FRANCISCO, CALIFORNIA, USA, March 4, 2024 /EINPresswire.com/ — GNQ Insilico Inc. (“GNQ”), a company developing a generative artificial intelligence and quantum computing platform to assist life sciences companies in...

Phoenix, Arizona--(Newsfile Corp. - November 11, 2020) - The Stock Day Podcast welcomed Agentix Biopharma (OTC Pink: AGTX) ("the Company"), a biotechnology company focused on the development of synthetic agonists,...